FIH (First in Human) Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation

• Status: Not yet recruiting
• Trial end date: 2023-03-03
• Target enrollment: 0
• Participant gender: All

Summary

A first-in-human single center, randomized, double-blind, placebo-controlled trial, with primary objective to evaluate safety and tolerability of ex-vivo kidney allograft treatment with TUM012 to reduce ischemia-reperfusion injury in de novo kidney transplant recipients.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: iCoat Medical AB
• Collaborators: CTC Clinical Trial Consultants AB; Region Skane

Criteria

Inclusion Criteria:

• Standard and extended criteria donor ≥18 years of age, suitable for clinical transplantation and preserved by cold storage.

• Available, personally signed and dated Informed Consent Form (ICF)

• Male or female Chronic Kidney Disease (CKD) patient ≥18 years of age, with Glomerular Filtration Rate (GFR) ≤15 mL/min, awaiting their first kidney transplantation

• ABO-compatible, negative pre-transplant CDC class I and II crossmatch with no Donor Specific Antibodies (DSA), defined as ≤1 000 Mean Fluorescent Intensity (MFI).

• Patient is suitable for surgery, as judged by the investigator

• Completed vaccination program for pneumococcal disease, varicella zoster, measles, and SARS-CoV-2 virus

Exclusion Criteria:

• Surgically induced injuries compromising ex-vivo treatment and/or transplant outcome, as judged by the transplantation surgeon

• Previously undergone any organ and/or cell transplantations

• Patients with positive CDC class I and/or II crossmatch, or negative CDC class I and II crossmatch with pre-existing DSA > 1,000 MFI

• ABO-incompatible DD KT

• Pregnant or breast-feeding woman

• Woman of child-bearing potential, unwilling to use an adequate contraceptive method

• Prior participation in clinical trial with (approved or non-approved) IMP within one month prior to screening for this trial.

• Prior malignancy diagnosis ≤5 years, except for adequately treated basal cell, or squamous cell skin cancer, and cervical carcinoma in situ

• Positive result for serum Human Immunodeficiency Virus (HIV), active hepatitis B-, or C-infection in pre-transplant evaluation

• Clinical signs of ongoing infectious disease, defined as C-Reactive Protein (CRP) >10, unless stable since >4 weeks (<50% increase)

• Concomitant severe conditions requiring treatment and close monitoring, e.g., cardiac failure >grade 3 New York Heart Association (NYHA), unstable coronary disease, or oxygen dependent Chronic Obstructive Pulmonary Disease (COPD)

• History of any other clinically significant disease or disorder which, in the opinion of the investigator, may either put the patient at increased risk because of participation in the trial, or influence the results or the patient's ability to participate in the trial

• Patient unlikely to comply with trial procedures, restrictions, and requirements (e.g., caused by substance abuse, concurrent medical condition, etc.), as judged by investigator